SynthesisJCO precision oncology2025

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.

Matthew Dankner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.